News >

Tucatinib Triplet Improves Survival in Advanced HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 21, 2019

Roger Dansey, MD, chief medical officer at Seattle Genetics

Roger Dansey, MD

Tucatinib combined with trastuzumab (Herceptin) and capecitabine (Xeloda) improved overall survival (OS) and progression-free survival (PFS) compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, according to topline findings from the phase II HER2CLIMB trial (NCT02614794).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication